Boston Globe names Merck KGaA one of “Top Places to Work”
Merck KGaA's businesses in Massachusetts have been ranked among the “Top Places to Work” by The Boston Globe. Read More »
Merck KGaA's businesses in Massachusetts have been ranked among the “Top Places to Work” by The Boston Globe. Read More »
Bayer has formed a Phase 3 clinical trial that will assess the safety and effectiveness of Nifurtimox, a formulation designed to treat children of all ages that have been diagnosed with Chagas disease. Read More »
CSL Behring's Phase 2b clinical trial involving AEGIS-I has turned in positive results. Read More »
Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease. Read More »
Akcea Therapeutics' Phase 1/2 trial involving IONIS-ANGPTL3-LRx has turned in positive results. Read More »
Alnylam Pharmaceuticals published results from its Phase 1 clinical trial involving inclisiran in The New England Journal of Medicine. Read More »
Bristol-Myers Squibb and Innate Pharma have released the interim effectiveness analysis of its Phase 1/2 trial involving the lirilumab and Opdivo combination. Read More »
Crescendo Biosciences gave four poster presentations showcasing Vectra DA at the American College of Rheumatology meeting in Washington D.C. this week. Read More »
The American Cancer Society has partnered with the CVS Health Foundation to present grants to 20 institutions across the United States for their Tobacco-Free Generation Campus Initiative. Read More »
Merck has received the R&D 100 Award from R&D magazine. Read More »
Janssen-Cilag International NV's STELARA has been approved by the European Commission to treat adult patients who have moderate-to-severe Crohn’s disease and did not respond well to or are immune to conventional therapy or a tumor necrosis factor alpha antagonist. Read More »
Biothera Pharmaceuticals recently presented new Phase 2 Imprime PGG preclinical data that will corroborate the drug’s ability to produce coordinated innate and adaptive immune responses that could increase the effectiveness of other checkpoint inhibitor therapies. Read More »
Imprimis Pharmaceuticals has reached a purchase and supply agreement with the specialty pharmacy division of one of the country’s biggest pharmacy benefits managers Read More »
Amgen plans to partner with Janssen Biotech to further assess the drug combination of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen. Read More »
Vemlidy, Gilead Sciences’s treatment for chronic hepatitis B virus with compensated liver disease, has been approved by the U,S. Food and Drug Administration. Read More »
The Prostate Cancer Foundation has revealed its new corporate identity, which includes the tagline “Curing Together.” Read More »
McKesson Specialty Health hosted its two-day 2016 Onmark Fall Leadership Summit in Orlando, Florida, featuring the possible transformation that community oncology practices are having to make so they can survive in the ever-evolving world of care based on value and payment reform. Read More »
Prime Therapeutics has released a guide on how to enroll in health insurance to avoid tax penalties. Read More »
Prime Therapeutics has released a report detailing the rising cost of autoimmune drugs. Read More »
The American Pharmacists Association recently hosted 650 pharmacists at its 2016 Joint Federal Pharmacy Seminar in Oxon Hill, Maryland. Read More »